Phreesia

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Munich, Bavaria, Germany - March 31 2023: Phreesia offers medical organizations a patient intake software to streamline administrative tasks, boost revenue, and enhance patient care.

Health Care

Here&#39;s Why Phreesia&#39;s Average Revenue Per Client Will Accelerate: Analyst

credit-card-networks-5

News

Price Target

Markets

Analyst Ratings

Trading Ideas

COLM

ISRG

RXST

TRMB

ZBIO

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Costco.Shutterstock

ANVS

ASTH

BROS

CAVA

COST

LNTH

MCHP

TASK

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

Phreesia Inc

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmagen Inc

PHarol SGPS SA

9 analysts have expressed a variety of opinions on Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Phreesia, revealing an average target of $31.33, a high estimate of $35.00, and a low estimate of $29.00. Marking an increase of 5.59%, the current average surpasses the previous average price target of $29.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1738188037_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Phreesia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joseph Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Phreesia. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Phreesia compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Phreesia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Phreesia's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Phreesia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Phreesia Better</h2>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Phreesia's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Phreesia showcased positive performance, achieving a revenue growth rate of 16.57% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -13.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -5.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phreesia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Phreesia: 9 Analysts Share Their Views

Piper Sandler analyst Jessica Tassan reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and raises the price target from $31 to $33.

Reiteration

Piper Sandler Reiterates Overweight on Phreesia, Raises Price Target to $33

Citigroup analyst Daniel Grosslight maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $31 to $35.

Citigroup Maintains Buy on Phreesia, Raises Price Target to $35

Needham analyst Ryan MacDonald reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $29 price target.

Needham Reiterates Buy on Phreesia, Maintains $29 Price Target

Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and raises the price target from $28 to $30.

Keybanc Maintains Overweight on Phreesia, Raises Price Target to $30

5 analysts have shared their evaluations of Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.0, a high estimate of $34.00, and a low estimate of $29.00. This upward trend is apparent, with the current average reflecting a 4.73% increase from the previous average price target of $29.60.
<img src="https://www.benzinga.com/files/images/story/2025/1736366458_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Phreesia by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joseph Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Phreesia compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Phreesia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Phreesia's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Phreesia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Phreesia Better</h2>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Phreesia: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Phreesia's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 16.57%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Phreesia's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Phreesia's ROE excels beyond industry benchmarks, reaching -5.69%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.9%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Phreesia's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Phreesia Stock: Analyst Perspectives (5 Ratings)

Growth in Phreesia Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) <a href="https://www.benzinga.com/general/health-care">average revenue per client</a> is poised to accelerate, according to RBC Capital Markets.
The Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591ed97d290fa70001e6c69b/sean-dodge">Analyst Sean Dodge</a> upgraded the rating for Phreesia from Sector Perform to Outperform. He also raised the price target from $24 to $32.
The Thesis: Historically, new client additions drove Phreesia's growth. The healthcare tech company has "recently realigned its efforts" to focus on monetizing its existing client base, Dodge said in an upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Phreesia's efforts are directed towards an increasingly larger proportion of growth being driven by existing clients, he added.
The company's average revenue per client remained almost flat for two years, the analyst stated. 
Throughout the fiscal third quarter, it grew by 3% year-on-year.
This metric could accelerate, he further stated. Why? The company&#8217;s Network Solutions is gaining momentum. 
Phreesia also benefits from "the cross-selling of several of its newer (but seasoned) provider add-ons." The company also signed new clients with "bigger initial solution bundles.&#8221; 
PHR Price Action: Shares of Phreesia had risen by 3.3% to $27.84 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41626748/global-payments-revenue-eps-come-in-below-q3-estimates-francisco-partners-to-acquire-advancedmd-bus">Global Payments Revenue, EPS Come In Below Q3 Estimates, Francisco Partners To Acquire AdvancedMD Business</a></li>
</ul>
Image: Shutterstock

Here's Why Phreesia's Average Revenue Per Client Will Accelerate: Analyst

RBC Capital analyst Sean Dodge upgrades Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) from Sector Perform to Outperform and raises the price target from $24 to $32.

Upgrades

RBC Capital Upgrades Phreesia to Outperform, Raises Price Target to $32

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) from $96 to $100. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares closed at $94.55 on Tuesday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted the price target for Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) from $31 to $34. Truist Securities analyst Jailendra Singh maintained a Buy rating. Phreesia shares closed at $24.14 on Tuesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) price target from $56 to $42. Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight. RxSight shares settled at $39.17 on Tuesday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Trimble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NYSE">TRMB</a>) price target from $77 to $88. Oppenheimer analyst Kristen Owen maintained an Outperform rating. Trimble shares closed at $74.12 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) price target from $40 to $35. Morgan Stanley analyst Vikram Purohit maintained an Overweight rating. Zenas BioPharma shares closed at $9.50 on Tuesday.  <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna boosted Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $339 to $375. Susquehanna analyst James Friedman maintained a Positive rating on the stock. Visa shares closed at $312.38 on Tuesday. See how other analysts view this stock.</li>
<li>Piper Sandler raised the price target for Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) from $56 to $64. Piper Sandler analyst Brad Milsaps maintained an Overweight rating. Synovus Financial shares settled at $55.14 on Tuesday. <a href="https://www.benzinga.com/quote/SNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) price target from $88 to $130. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. United Airlines shares closed at $96.53 on Tuesday. <a href="https://www.benzinga.com/quote/UAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from $549 to $630. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating. Intuitive Surgical shares closed at $538.09 on Tuesday. <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Columbia Sportswear Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) price target from $92 to $100. Stifel analyst Jim Duffy maintained a Buy rating. Columbia Sportswear shares closed at $90.09 on Tuesday. <a href="https://www.benzinga.com/quote/COLM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42432935/top-3-health-care-stocks-that-may-collapse-this-quarter">Top 3 Health Care Stocks That May Collapse This Quarter</a></li>
</ul>

Analysts' ratings for Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.2, along with a high estimate of $34.00 and a low estimate of $23.00. Highlighting a 0.68% decrease, the current average has fallen from the previous average price target of $29.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1733929235_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Phreesia is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joseph Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Phreesia. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Phreesia compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Phreesia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Phreesia's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Phreesia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Phreesia Better</h2>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Understanding the Numbers: Phreesia's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Phreesia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.57% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Phreesia's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Phreesia's ROE excels beyond industry benchmarks, reaching -5.69%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Phreesia's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $31 to $34.

Truist Securities Maintains Buy on Phreesia, Raises Price Target to $34

Baird analyst Joseph Vruwink maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Outperform and lowers the price target from $34 to $30.

Baird Maintains Outperform on Phreesia, Lowers Price Target to $30

JMP Securities analyst Aaron Kimson reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Market Outperform and maintains $30 price target.

JMP Securities Reiterates Market Outperform on Phreesia, Maintains $30 Price Target

Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) released its Q3 earnings on Monday, December 9, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Phreesia beat estimated earnings by 14.000000000000002%, reporting an EPS of $-0.25 versus an estimate of $-0.29.
Revenue was up $15.18 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.05, leading to a 6.0% increase share price change the next day.
Here's a look at Phreesia's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.48</td>
<td>-0.26</td>
<td>-0.36</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.35</td>
<td>-0.56</td>
<td>-0.58</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>101.70M</td>
<td>100.97M</td>
<td>93.53M</td>
<td>89.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>102.11M</td>
<td>101.22M</td>
<td>95.00M</td>
<td>91.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Phreesia <a href="https://www.benzinga.com/quote/PHR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Phreesia Earnings Review: Q3 Summary

Guidance

Phreesia Expects FY26 Revenue Of $472M - $482M, Est $480.856M

Phreesia Narrows FY25 Revenue Outlook From $416M - $426M To $418M - $420M, Est $419.213M

Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $106.80 million which beat the analyst consensus estimate of $106.33 million by 0.44 percent. This is a 16.57 percent increase over sales of $91.62 million the same period last year.

Earnings Beats

Phreesia Q3 2025 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $106.80M Beat $106.33M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) is likely to report quarterly loss at $4.45 per share on revenue of $76.05 million. 
• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $29.20 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $366.41 million. 
<h3>Companies Reporting After The Bell</h3>
• Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) is projected to report quarterly earnings at $4.27 per share on revenue of $4.02 billion. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is estimated to report quarterly earnings at $4.34 per share on revenue of $3.17 billion. 
• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $495.72 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is likely to report quarterly loss at $4.98 per share on revenue of $251.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.11 per share on revenue of $9.03 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.29 per share on revenue of $106.00 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $290.00 million. 
• Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $23.75 million. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.48 per share on revenue of $14.11 billion. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is projected to report quarterly loss at $0.01 per share on revenue of $148.19 million. 
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $113.21 million. 
• C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) is expected to report quarterly loss at $0.16 per share on revenue of $91.02 million. 
• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is likely to report quarterly loss at $0.04 per share on revenue of $63.12 million. 
• Oil-Dri Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASYS

BRZE

CASY

GNSS

MOMO

ORCL

RENT

VBNK

YEXT

Earnings Scheduled For December 9, 2024

Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) will release its quarterly earnings report on Monday, 2024-12-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Phreesia to report an earnings per share (EPS) of $-0.27.
The market awaits Phreesia's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 6.29% increase in the share price the next day.
Here's a look at Phreesia's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.48</td>
<td>-0.26</td>
<td>-0.36</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.35</td>
<td>-0.56</td>
<td>-0.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>-11.0%</td>
<td>5.0%</td>
<td>21.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1733493789_0.png" alt="eps graph" />
<h3>Analyst Insights on Phreesia</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Phreesia.
Phreesia has received a total of 2 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $25.5, the consensus suggests a potential 20.68% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Evolent Health, HealthStream and Schrodinger, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Evolent Health is favoring an Outperform trajectory, with an average 1-year price target of $26.3, suggesting a potential 24.47% upside.</li>
<li>As per analysts' assessments, HealthStream is favoring an Neutral trajectory, with an average 1-year price target of $31.5, suggesting a potential 49.08% upside.</li>
<li>For Schrodinger, analysts project an Outperform trajectory, with an average 1-year price target of $26.5, indicating a potential 25.41% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for Evolent Health, HealthStream and Schrodinger, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phreesia</td>
<td>Neutral</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
<tr>
<td>Evolent Health</td>
<td>Outperform</td>
<td>21.60%</td>
<td>$80.69M</td>
<td>-2.99%</td>
</tr>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>3.92%</td>
<td>$48.62M</td>
<td>1.62%</td>
</tr>
<tr>
<td>Schrodinger</td>
<td>Outperform</td>
<td>-17.10%</td>
<td>$17.73M</td>
<td>-8.26%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Phreesia ranks at the top for Revenue Growth among its peers, showing the highest percentage increase. It is at the bottom for Gross Profit, indicating the lowest profit margin. In terms of Return on Equity, Phreesia is also at the bottom, reflecting a negative percentage. Overall, Phreesia's performance is mixed compared to its peers, excelling in revenue growth but lagging in profitability and return on equity.
<h3>Discovering Phreesia: A Closer Look</h3>
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
<h3>Breaking Down Phreesia's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Phreesia displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 18.97%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Phreesia's net margin is impressive, surpassing industry averages. With a net margin of -17.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phreesia's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.91%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/PHR/earnings">To track all earnings releases for Phreesia visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Phreesia

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga